Omeros (NASDAQ:OMER) Now Covered by D. Boral Capital

Analysts at D. Boral Capital started coverage on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s target price points to a potential upside of 249.18% from the company’s previous close.

OMER has been the subject of a number of other reports. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Rodman & Renshaw began coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Thursday. Finally, RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Up 0.7 %

NASDAQ OMER opened at $10.31 on Monday. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60. The stock’s fifty day moving average price is $7.09 and its 200-day moving average price is $5.20. The stock has a market cap of $597.46 million, a P/E ratio of -4.46 and a beta of 1.97.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently made changes to their positions in OMER. Wellington Management Group LLP purchased a new stake in Omeros during the third quarter valued at approximately $305,000. Barclays PLC increased its stake in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 51,873 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the period. AQR Capital Management LLC bought a new stake in Omeros during the second quarter valued at about $105,000. Finally, SG Americas Securities LLC purchased a new stake in Omeros in the third quarter worth about $80,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.